ClinicalTrials.gg
CompletedNCT05422378Updated Mar 18, 2024

A Study to Evaluate Safety, Tolerability of Subcutaneous Injection in Adult Subjects Undergoing Abdominoplasty

A Phase 1 interventional study of STP705 in Abdominal Obesity, sponsored by Sirnaomics. Completed at 1 site in United States. Open to participants aged 18 Years to 65 Years. Per ClinicalTrials.gov, last updated 2024-03-18.

Sponsored by Sirnaomics · Phase 1, Interventional, and Treatment

From the registry’s dates

  • Primary completion was Feb 2023, 3 years 9 months ago, and no results have been posted to the registry.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
8
Allocation
Randomized
Ages
18 Years to 65 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 57 studies in Obesity, Abdominal with a site in United States — 7 open to participants now, 10 under way, 1 of them phase 3. Obesity, Abdominal · United States.

Enrollment
50th of 53
8 · median 40
Started
2022
with 2 others
Phase 1
Only one
of the 57
Registered
49th of 57
by date

Among the 57 studies in Obesity, Abdominal with a site in United States, this one is the 50th largest by enrollment of the 53 interventional ones that give a count, is one of 3 that started in 2022, is the only one in phase 1, and was the 49th registered.

Obesity, Abdominal

295 studies on the registry are indexed under Obesity, Abdominal; 45 are open to participants now.

Browse Obesity, Abdominal studies →

Open to participants now

7 of the 57 studies in Obesity, Abdominal with a site in United States are open now. Recruiting first, the newest first:

2 more — sign in →

All 7 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 26 Obesity, Abdominal studies recruiting now, 3 (12%) set no upper age limit and 21 (81%) stop at 75 or younger; 1 takes children under 18; 10 take healthy volunteers.

This study: 18 Years to 65 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 57 studies in Obesity, Abdominal with a site in United States, or all of them as a file.
02

Study summary

Dose-ranging, randomized, double-blind, vehicle-controlled study

Read the detailed description

Subject will receive a single injection for each treatment which all 3 test article concentrations and both injection volumes and the vehicle for a total of 7 treatments.

Subjects will receive test articles in 3 visits.

03

Conditions studied

  • Abdominal Obesity

Browse trials for

04

Who can participate

Ages eligible
18 Years to 65 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

To enter the study, a subject must meet the following criteria:

  1. Subject is a male or non-pregnant female 18-65 years of age.
  2. Subject has provided written .
  3. Females must be , surgically sterile , or use an effective method of . , Women of (WOCBP) must have a negative urine pregnancy test (UPT) at Visit 1/Screening and Visit 3/Baseline.
  4. Subject has agreed to undergo an abdominoplasty procedure, participate in this study, has minimally acceptable adipose tissue in the target areas per protocol, and meets all pre-operative requirements, in the opinion of the investigator and surgeon.

Exclusion criteria

Exclusion Criteria:

A subject is ineligible to enter the study if he/she meets one or more of the following criteria:

  1. Subject is pregnant, lactating, or is planning to become pregnant during the study.
  2. Subject has a significant active systemic or localized abdominal infection.
  3. Subject has a (BMI) ≥40.
  4. Subject has any medical condition that affects clotting and/or function (e.g., thromboembolic disease, clotting factor deficiencies such as hemophilia).
  5. Subject is taking any medications that affect clotting and/or platelet function. This includes, but is not limited to, heparin (including low molecular weight heparin), Coumadin, and factor Xa agents such as apixaban (Eliquis), etc. The use of such medications is precluded up to 7 days prior to Visit 3/Baseline and during the study period.
  6. Subject is , in the opinion of the investigator, based on their medical condition (e.g., positive, ), medication use, or other factors.
  7. Subject has any medical abnormality or chronic disease of the cardiovascular, gastrointestinal, respiratory (e.g., ), hepatic, or renal systems. This includes conditions (e.g., gastrointestinal surgery) that may interfere with metabolism or excretion.
  8. Subject has local skin condition(s) (e.g., rash, scarring, and tattoos) or inadequate injection sites in the region designated for abdominoplasty excision which are inappropriate for participation in the study, in the opinion of the investigator.
  9. Subject is currently enrolled in an drug, biologic, or device study.
  10. Subject has used an investigational drug, investigational biologic, or investigational device treatment within 30 days prior to first injection of the test article.
  11. Subject has a history of sensitivity to any of the ingredients in the test articles (see Section 6.1).
  12. Subject is known to be noncompliant or is unlikely to comply with the requirements of the study protocol (e.g., due to alcoholism, drug dependency, mental incapacity) in the opinion of the investigator.
Terms in these criteria, in plain language(12)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

COPD

Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
8 participants (actual)

Study arms

  • Experimental
    STP705, 120ug/mL, 0.5 cc

    Volume of Injection 0.5cc

    Drug: STP705

  • Experimental
    STP705, 120ug/mL, 1.0 cc

    Volume of Injection 1.0cc

    Drug: STP705

  • Experimental
    STP705, 240 ug/mL, 0.5 cc

    Volume of Injection 0.5cc

    Drug: STP705

  • Experimental
    STP705, 240ug/mL, 1.0 cc

    Volume of Injection 1.0cc

    Drug: STP705

  • Experimental
    STP705, 320ug/mL, 0.5 cc

    Volume of Injection 0.5cc

    Drug: STP705

  • Experimental
    STP705, 320ug/mL, 1.0 cc

    Volume of Injection 1.0cc

    Drug: STP705

  • Placebo comparator
    Vehicle

    1.0cc placebo

    Drug: STP705

Interventions

  • DrugSTP705

    STP705 composed of 2 siRNA targeting TGF-B1and COX-2 individually.

    Also known as: STP705 Powder for Injection

06

What researchers measure

Primary outcomes

  1. Number of subjects with presence and severity of the following Local Skin Reactions (LSR): erythema, edema, bruising.

    LSR scale will be used by investigator to assess injection site using a 4-point ordinal scale (0=complete absence, 1=mild, limited involvement, 2= moderate involvement, and 3= severe, extreme involvement)

    Time frame: 24 weeks

  2. Number of subjects with presence and severity of the following Local Skin Reactions (LSR): pain and stinging/burning.

    LSR scale will be used by subjects to assess injection site using a 4-point ordinal scale (0=complete absence, 1=mild, 2= moderate, and 3= severe)

    Time frame: 24 weeks

  3. Incidence (severity and causality) of any AEs

    AE's will be classified using CTCAE v.5.0

    Time frame: 24 weeks

07

Study locations

1 site
  • Center for Clinical and Cosmetic Research
    Aventura, Florida 33180, United States
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Aug 2022 to primary completion in Feb 2023, 6 months.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 8, 2022
First posted
Jun 16, 2022
StartActual
Aug 1, 2022
Primary completionActual
Feb 3, 2023
CompletionActual
Jun 27, 2023
Last update
Mar 18, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Mar 18, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT05422378
Lead sponsor
Sirnaomics
Responsible party
Sponsor
First posted
Jun 16, 2022
Start date
Aug 1, 2022
Primary completion
Feb 3, 2023
Completion
Jun 27, 2023
Last update
Mar 18, 2024

Study contacts

Mark Nestor, MD
principal investigator · Center for Clinical and Cosmetic Research

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Mar 2024. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Cotsiranib

Start the discussion